Inflammatory bowel disease course in Crohn???s disease: Is the natural history changing?, World Journal of Gastroenterology, vol.20, issue.12, pp.3198-207, 2014. ,
DOI : 10.3748/wjg.v20.i12.3198
Maladie de Crohn et rectocolite hémorragique, Paris: Medi-text éd, 2005. ,
Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis, World Journal of Gastroenterology, vol.20, issue.29, pp.9872-81, 2014. ,
DOI : 10.3748/wjg.v20.i29.9872
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health, Gut, vol.61, issue.2, pp.241-248, 2012. ,
DOI : 10.1136/gutjnl-2011-300049
URL : https://hal.archives-ouvertes.fr/hal-00683372
Maladies inflammatoires chroniques de l'intestin. Rueil- Malmaison: Doin, 2009. ,
Prise en charge des MICI, Montrouge: J. Libbey Eurotext, 2003. ,
Maladie de Crohn de l'adulte. EMC -Gastro-Entérologie, janv, vol.2, issue.3, pp.1-18, 2007. ,
Inflammatory bowel disease: Pathogenesis, World Journal of Gastroenterology, vol.20, issue.1, pp.91-100, 2014. ,
DOI : 10.3748/wjg.v20.i1.91
Environmental Risk Factors for Inflammatory Bowel Diseases: A Review, Digestive Diseases and Sciences, vol.141, issue.Suppl 2, pp.367-74, 2013. ,
DOI : 10.1007/s10620-014-3350-9
Traité de gastro-entérologie. Paris: Médecine-sciences Flammarion, 2005. ,
A clinical review of recent findings in the epidemiology of inflammatory bowel disease, Clin Epidemiol, vol.5, pp.237-284, 2013. ,
Association nationale des enseignants de pharmacie clinique. Pharmacie clinique et thérapeutique, 2008. ,
Les maladies inflammatoires chroniques de l'intestin. ohn Libbey Eurotext, 1999. ,
Extraintestinal manifestations of inflammatory bowel disease: Do they influence treatment and outcome?, World Journal of Gastroenterology, vol.17, issue.22, pp.2702-2709, 2011. ,
DOI : 10.3748/wjg.v17.i22.2702
Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management, Annals of Medicine, vol.9, issue.7, pp.97-114, 2010. ,
DOI : 10.2165/00002018-200023050-00006
Les manifestations articulaires associées aux maladies inflammatoires chroniques de l'intestin. Hépato-Gastro Oncol Dig. 1 mars, pp.36-42, 2011. ,
Manifestations extradigestives des maladies inflammatoires chroniques intestinales, AKOS, 2013. ,
Les manifestations articulaires associées aux maladies inflammatoires chroniques de l'intestin. Hépato-Gastro Oncol Dig. 1 mars, pp.36-42, 2011. ,
L??sions ost??o-articulaires au cours des maladies inflammatoires chroniques de l???intestin, Gastroent??rologie Clinique et Biologique, vol.28, issue.5, pp.75-82, 2004. ,
DOI : 10.1016/S0399-8320(04)94991-3
Extraintestinal manifestations and complications in inflammatory bowel diseases, World J Gastroenterol WJG. 14 août, vol.12, issue.30, pp.4819-4850, 2006. ,
Paris: Ellipses, 2005. ,
Management of intestinal strictures in inflammatory bowel disease, Acta Endoscopica, vol.6, issue.3, pp.129-162, 2013. ,
DOI : 10.1007/s10190-013-0316-2
Nutrition en pathologie digestive, 2007. ,
Conséquences nutritionnelles des maladies inflammatoires cryptogénétiques de l'intestin. Hépato-Gastro, pp.123-157, 2005. ,
Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk?, World Journal of Gastroenterology, vol.18, issue.29, pp.3839-3887, 2012. ,
DOI : 10.3748/wjg.v18.i29.3839
Biomarkers in management of inflammatory bowel disease, Gastroenterology Review, vol.5, issue.5, pp.275-83, 2013. ,
DOI : 10.5114/pg.2013.38728
Utility of serological markers in inflammatory bowel diseases: Gadget or magic?, World Journal of Gastroenterology, vol.13, issue.14, pp.2028-2064, 2007. ,
DOI : 10.3748/wjg.v13.i14.2028
Actualité du diagnostic des MICI. [cité 3 sept 2014]; Disponible sur ,
Review: Optimal use of biologics in the management of Crohn???s disease, Therapeutic Advances in Gastroenterology, vol.354, issue.2, pp.179-89, 2010. ,
DOI : 10.1177/1756283X09357579
Quand débuter un traitement anti-TNF? 2014 [cité 6 sept 2014]; Disponible sur ,
Agence nationale de sécurité du médicament et des produits de santé ,
Pharmacologie et classification des inhibiteurs de la cyclooxyg??nase, Gastroent??rologie Clinique et Biologique, vol.28, issue.3, pp.7-17, 2004. ,
DOI : 10.1016/S0399-8320(04)95274-8
Pr??vention des complications digestives des anti-inflammatoires non st??ro??diens??: de la connaissance des facteurs de risque ?? leur prise en compte, Revue du Rhumatisme, vol.77, issue.1, pp.7-13, 2010. ,
DOI : 10.1016/j.rhum.2009.04.008
Analyse des ventes de médicaments aux officines et aux hôpitaux en France de 1998 à 2008 -rapport Afssaps, 2010. ,
Les anti-inflammatoires non st??ro??diens, Actualit??s Pharmaceutiques, vol.48, issue.489, pp.53-59, 2009. ,
DOI : 10.1016/S0515-3700(09)70516-6
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, BMJ, vol.329, issue.7456, pp.15-24, 2004. ,
DOI : 10.1136/bmj.329.7456.15
Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology, Trends in Molecular Medicine, vol.14, issue.10, pp.461-470, 2008. ,
DOI : 10.1016/j.molmed.2008.08.005
Pharmacologie fondamentale et clinique, 2006. ,
Clinical pharmacology of nonsteroidal anti-inflammatory drugs: a review. Anti-Inflamm Anti, Allergy Agents Med Chem, vol.11, issue.1, pp.52-64, 2012. ,
Bases chimiques et pharmacologiques des AINS, Revue Fran??aise d'Allergologie, vol.54, issue.3, pp.212-219, 2014. ,
DOI : 10.1016/j.reval.2014.01.026
Paris: Flammarion médecine-sciences, 2005. ,
De Boeck Supérieur, 1997. ,
Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag, janv, vol.10, issue.6, pp.25-32, 2014. ,
Les anti-inflammatoires non st??ro??diens, Actualit??s Pharmaceutiques, vol.53, issue.534, pp.43-49, 2014. ,
DOI : 10.1016/j.actpha.2014.01.009
GPC 2013: guide pharmaco clinique. [Rueil- Malmaison]: le Moniteur des pharmacies, 2013. ,
Wolters Kluwer France, p.91, 2007. ,
Guide du bon usage du médicament ,
Information transmise par l'ANSM. Diclofénac par voie systémique -nouvelles contre-indications et mises en garde après une revue européenne de son profil de sécurité cardiovasculaire, 2013. ,
Traitements anti-inflammatoires. Place des AINS classiques et des coxibs, EMC - M??decine, vol.2, issue.5, pp.524-555, 2005. ,
DOI : 10.1016/j.emcmed.2005.08.004
Complications intestinales li??es aux AINS, Gastroent??rologie Clinique et Biologique, vol.28, pp.62-72, 2004. ,
DOI : 10.1016/S0399-8320(04)95280-3
Complications ??sophagiennes des m??dicaments anti-inflammatoires non st??ro??diens, Gastroent??rologie Clinique et Biologique, vol.28, issue.3, pp.58-61, 2004. ,
DOI : 10.1016/S0399-8320(04)95279-7
Toxicit?? gastroduod??nale des m??dicaments anti-inflammatoires non st??ro??diens, EMC - Gastro-ent??rologie, vol.1, issue.1, p.11, 2003. ,
DOI : 10.1016/S1155-1968(03)00070-1
NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies, British Journal of Pharmacology, vol.298, issue.1, pp.67-74, 2012. ,
DOI : 10.1111/j.1476-5381.2011.01509.x
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252967
Physiopathologie des l??sions gastro-duod??nales induites par les anti-inflammatoires non st??ro??diens, Gastroent??rologie Clinique et Biologique, vol.28, pp.18-26, 2004. ,
DOI : 10.1016/S0399-8320(04)95275-X
Current Perspectives in NSAID-Induced Gastropathy, Mediators of Inflammation, vol.44, issue.5, pp.1-11, 2013. ,
DOI : 10.1016/j.abb.2010.05.026
The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine, Journal of Clinical Biochemistry and Nutrition, vol.48, issue.2, pp.107-118, 2011. ,
DOI : 10.3164/jcbn.10-79
Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans, Gastroenterology, vol.117, issue.1, pp.17-25, 1999. ,
DOI : 10.1016/S0016-5085(99)70545-7
Digestive and hemorrhage complications of low-dose aspirin]. Presse Médicale Paris Fr 1983, 22 nov, vol.32, pp.17-28, 2003. ,
Recent considerations in nonsteroidal anti-inflammatory drug gastropathy, The American Journal of Medicine, vol.105, issue.1, pp.31-38, 1998. ,
DOI : 10.1016/S0002-9343(98)00072-2
A Quantitative Analysis of NSAID-Induced Small Bowel Pathology by Capsule Enteroscopy, Gastroenterology, vol.128, issue.5, pp.1172-1180, 2005. ,
DOI : 10.1053/j.gastro.2005.03.020
The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium, Journal of Clinical Biochemistry and Nutrition, vol.54, issue.1, pp.2-6, 2014. ,
DOI : 10.3164/jcbn.13-84
Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy, World Journal of Gastroenterology, vol.19, issue.12, pp.1861-76, 2013. ,
DOI : 10.3748/wjg.v19.i12.1861
Multiple NSAID-Induced Hits Injure the Small Intestine: Underlying Mechanisms and Novel Strategies, Toxicological Sciences, vol.131, issue.2, pp.654-67, 2013. ,
DOI : 10.1093/toxsci/kfs310
Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man., Gut, vol.32, issue.3, pp.275-282, 1991. ,
DOI : 10.1136/gut.32.3.275
Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs, AJP: Gastrointestinal and Liver Physiology, vol.298, issue.5, pp.722-753, 2010. ,
DOI : 10.1152/ajpgi.00387.2009
Disponible sur: https://www.fmcgastro.org/wp-content, 2014. ,
Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: Role of bile salts, Clinical Biochemistry, vol.40, issue.8, pp.503-513, 2007. ,
DOI : 10.1016/j.clinbiochem.2007.01.015
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?, European Journal of Clinical Pharmacology, vol.104, issue.5, pp.963-70, 2009. ,
DOI : 10.1007/s00228-009-0719-3
URL : https://hal.archives-ouvertes.fr/hal-00534990
Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage, Arthritis Research & Therapy, vol.15, issue.Suppl 3, p.3, 2013. ,
DOI : 10.1186/ar4175
URL : http://doi.org/10.1186/ar4175
Impact of environmental and dietary factors on the course of inflammatory bowel disease, World Journal of Gastroenterology, vol.18, issue.29, pp.3814-3836, 2012. ,
DOI : 10.3748/wjg.v18.i29.3814
Inflammatory bowel disease: role of diet, microbiota, life style, Translational Research, vol.160, issue.1, pp.29-44, 2012. ,
DOI : 10.1016/j.trsl.2011.09.001
Environmental influences on the onset and clinical course of Crohn's disease-part 2: infections and medication use, Gastroenterol Hepatol. déc, vol.9, issue.12, pp.803-813, 2013. ,
Environmental Triggers for Inflammatory Bowel Disease, Current Gastroenterology Reports, vol.105, issue.Suppl 2, p.302, 2013. ,
DOI : 10.1007/s11894-012-0302-4
Familial aggregation in inflammatory bowel disease: Is it genes or environment?, World Journal of Gastroenterology, vol.17, issue.22, pp.2715-2737, 2011. ,
DOI : 10.3748/wjg.v17.i22.2715
Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs., Postgraduate Medical Journal, vol.57, issue.667, pp.297-306, 1981. ,
DOI : 10.1136/pgmj.57.667.297
Nonsteroidal Anti-Inflammatory Drugs Activate Quiescent Inflammatory Bowel Disease, Annals of Internal Medicine, vol.107, issue.4, pp.513-519, 1987. ,
DOI : 10.7326/0003-4819-107-4-513
Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors., Gut, vol.31, issue.12, pp.1358-64, 1990. ,
DOI : 10.1136/gut.31.12.1358
Studies of gut mucosal protein synthesis in a non-steroidal anti-inflammatory drug (NSAID) model of inflammatory bowel disease., Gut, vol.33, issue.2, pp.242-247, 1992. ,
DOI : 10.1136/gut.33.2.242
Using COX-2 inhibitors in IBD: anti-inflammatories inflame a controversy, The American Journal of Gastroenterology, vol.43, issue.4, pp.783-788, 2002. ,
DOI : 10.1016/S0002-9270(98)00469-9
Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: Fact or fiction, World Journal of Gastroenterology, vol.12, issue.10, pp.1509-1519, 2006. ,
DOI : 10.3748/wjg.v12.i10.1509
Selective use of selective nonsteroidal antiinflammatory drugs in inflammatory bowel disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. févr, vol.4, issue.2, pp.157-166, 2006. ,
Managing Pain in Inflammatory Bowel Disease, Gastroenterol Hepatol. sept, vol.7, issue.9, pp.592-601, 2011. ,
Pain management in patients with inflammatory bowel disease: insights for the clinician, Therapeutic Advances in Gastroenterology, vol.5, issue.5, pp.339-57, 2012. ,
DOI : 10.1177/1756283X12446158
Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study, The American Journal of Gastroenterology, vol.41, issue.8, pp.1949-54, 2000. ,
DOI : 10.1016/S0140-6736(84)92739-9
Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease, The American Journal of Gastroenterology, vol.115, issue.8, 2000. ,
DOI : 10.1001/archinte.152.3.625
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease, The American Journal of Gastroenterology, vol.157, issue.5, pp.910-914, 2002. ,
DOI : 10.1056/NEJM200006293422603
An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia, Alimentary Pharmacology and Therapeutics, vol.115, issue.11, pp.1371-80, 2003. ,
DOI : 10.1111/j.1572-0241.2002.07142.x
Exacerbation of inflammatory bowel disease associated with use of celecoxib, The American Journal of Gastroenterology, vol.115, issue.4, pp.1306-1314, 2001. ,
DOI : 10.1056/NEJM199406303302601
Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis, Annals of Internal Medicine, vol.156, issue.5, pp.350-359, 2012. ,
DOI : 10.7326/0003-4819-156-5-201203060-00007
Aspirin in the aetiology of Crohn???s disease and ulcerative colitis: a European prospective cohort study, Alimentary Pharmacology & Therapeutics, vol.125, issue.Suppl., pp.649-55, 2011. ,
DOI : 10.1111/j.1365-2036.2011.04784.x
Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug???Induced Clinical Relapse in Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.196-202, 2006. ,
DOI : 10.1016/S1542-3565(05)00980-8
Relapse of Inflammatory Bowel Disease Associated With Use of Nonsteroidal Anti-Inflammatory Drugs, Digestive Diseases and Sciences, vol.92, issue.1, pp.168-72, 2006. ,
DOI : 10.1007/s10620-006-3103-5
A Long-term Cohort Study of Nonsteroidal Anti-inflammatory Drug Use and Disease Activity in Outpatients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.6, pp.751-758, 2004. ,
DOI : 10.1097/00054725-200411000-00009
The Gastrointestinal Safety and Effect on Disease Activity of Etoricoxib, a Selective Cox-2 Inhibitor in Inflammatory Bowel Diseases, The American Journal of Gastroenterology, vol.4, issue.4, pp.311-318, 2006. ,
DOI : 10.1056/NEJMoa021907
Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.203-214, 2006. ,
DOI : 10.1016/j.cgh.2005.12.002
Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial, Alimentary Pharmacology and Therapeutics, vol.122, issue.3, pp.755-64, 2004. ,
DOI : 10.1056/NEJM200011233432103
The Spectrum of Gastrointestinal Toxicity and Effect on Disease Activity of Selective Cyclooxygenase-2 Inhibitors in Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.4, pp.352-358, 2004. ,
DOI : 10.1097/00054725-200407000-00005
Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease., Gut, vol.40, issue.5, pp.619-641, 1997. ,
DOI : 10.1136/gut.40.5.619
Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis, Current Therapeutic Research, vol.69, issue.3, pp.181-91, 2008. ,
DOI : 10.1016/j.curtheres.2008.06.009
Do NSAIDs, Antibiotics, Infections, or Stress Trigger Flares in IBD?, The American Journal of Gastroenterology, vol.89, issue.5, pp.1298-313, 2009. ,
DOI : 10.1037/0278-6133.21.6.531
Do Non-steroidal Anti-inflammatory Drugs Cause Exacerbations of Inflammatory Bowel Disease?, Digestive Diseases and Sciences, vol.31, issue.2, pp.226-258, 2010. ,
DOI : 10.1007/s10620-009-1042-7
Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease, Pharmaceuticals, vol.3, issue.4, pp.1084-92, 2010. ,
DOI : 10.3390/ph3041084
Comment permettre aux patients de d??crypter l???information sur Internet??? Construction d???un outil d?????valuation des sites d???information sant?? ?? destination des patients, Le Pharmacien Hospitalier et Clinicien, vol.49, issue.2 ,
DOI : 10.1016/j.phclin.2014.04.330